Display options
Cite
Paquet J, Moya A, Bensidhoum M, et al. Engineered cell-free scaffold with two-stage delivery of miRNA-26a for bone repair. Ann Transl Med. 2016;4(10):204doi: 10.21037/atm.2016.05.28.
Paquet, J., Moya, A., Bensidhoum, M., & Petite, H. (2016). Engineered cell-free scaffold with two-stage delivery of miRNA-26a for bone repair. Annals of translational medicine, 4(10), 204. https://doi.org/10.21037/atm.2016.05.28
Paquet, Joseph, et al. "Engineered cell-free scaffold with two-stage delivery of miRNA-26a for bone repair." Annals of translational medicine vol. 4,10 (2016): 204. doi: https://doi.org/10.21037/atm.2016.05.28
Paquet J, Moya A, Bensidhoum M, Petite H. Engineered cell-free scaffold with two-stage delivery of miRNA-26a for bone repair. Ann Transl Med. 2016 May;4(10):204. doi: 10.21037/atm.2016.05.28. PMID: 27294100; PMCID: PMC4885895.
Copy Download .nbib Format: NLM
Share it on

Ann Transl Med. 2016 May;4(10):204. doi: 10.21037/atm.2016.05.28.

Engineered cell-free scaffold with two-stage delivery of miRNA-26a for bone repair.

Annals of translational medicine

Joseph Paquet, Adrien Moya, Morad Bensidhoum, Hervé Petite

Affiliations

  1. Laboratoire de Bioingénierie et Bioimagerie Ostéo-Articulaires (B2OA - UMR CNRS 7052) Université Paris Diderot, 10 Avenue de Verdun, 75010 Paris, France.

PMID: 27294100 PMCID: PMC4885895 DOI: 10.21037/atm.2016.05.28

Abstract

The treatment of non-unions and bone defects is a major challenge. In these situations, autologous bone is the preferred treatment but has several serious limitations. Treatment alternatives including the use of calcium-based scaffolds alone or associated with either growth factors or stem cells have therefore been developed, or are under development, to overcome these shortcomings. Each of these are, however, associated with their own drawbacks, such as the lack of sustained/controlled delivery system for growth factors and poor cell survival and engraftment for stem cells. MicroRNAs (miRNAs), a class of small noncoding RNAs fine-tune the expression of as much as 30% of all mammalian protein-encoding genes. For instance, miRNA26a is able to promote the repair of critical-size calvarial bone defects. Yet, the clinical application of these fascinating molecules has been hampered by a lack of appropriate delivery systems. In an elegant report entitled cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects, Zhang et al. 2016, developped a non-viral vector with high affinity to miR-26a that ensured its efficient delivery in bone defects. Engineered scaffolds were able to induce the regeneration of calvarial bone defects in healthy and osteoporotic mice. Taken together, these data pave the way for the development of advanced bone substitutes that at least will match, and preferably supersede, the clinical efficiency of autologous bone grafts. However, the transfer from the bench to the bedside of such scaffolds requires further investigations including (I) a better understanding of the underlying biological mechanisms involved in bone formation via miRNA26a; (II) evidences of polymer scaffold biocompatibility upon its complete degradation; and (III) demonstration of the engineered scaffold functionality in defects of clinically relevant volume.

Keywords: Bone; bone grafts; microRNAs (miRNAs); scaffold

References

  1. J Orthop Trauma. 1989;3(3):192-5 - PubMed
  2. Biomaterials. 2013 Jul;34(21):5048-58 - PubMed
  3. Nat Biotechnol. 2000 Sep;18(9):959-63 - PubMed
  4. J Cell Biochem. 2007 Dec 15;102(6):1504-18 - PubMed
  5. J Mater Sci Mater Med. 2014 Oct;25(10):2445-61 - PubMed
  6. Nature. 2004 Sep 16;431(7006):350-5 - PubMed
  7. J Cell Mol Med. 2005 Jan-Mar;9(1):72-84 - PubMed
  8. J Foot Ankle Surg. 1996 Sep-Oct;35(5):413-7 - PubMed
  9. Biomaterials. 1994 Dec;15(15):1209-13 - PubMed
  10. Nat Commun. 2016 Jan 14;7:10376 - PubMed
  11. Spine J. 2014 Mar 1;14(3):552-9 - PubMed
  12. J Orthop Res. 2007 Jun;25(6):741-9 - PubMed
  13. Cell. 2004 Jan 23;116(2):281-97 - PubMed
  14. J Bone Miner Res. 2006 Jun;21(6):910-20 - PubMed
  15. Curr Opin Biotechnol. 2004 Oct;15(5):392-8 - PubMed
  16. Biomaterials. 2006 Jun;27(18):3413-31 - PubMed
  17. Cell. 2009 Jan 23;136(2):215-33 - PubMed
  18. Biomaterials. 2007 Oct;28(29):4240-50 - PubMed
  19. Biomaterials. 2006 Oct;27(29):5027-38 - PubMed
  20. J Bone Joint Surg Am. 1998 Jul;80(7):985-96 - PubMed

Publication Types